120 related articles for article (PubMed ID: 33377050)
1. An Improved Protocol for Establishment of AML Patient-Derived Xenograft Models.
Hassan N; Yang J; Wang JY
STAR Protoc; 2020 Dec; 1(3):100156. PubMed ID: 33377050
[TBL] [Abstract][Full Text] [Related]
2. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.
Saland E; Boutzen H; Castellano R; Pouyet L; Griessinger E; Larrue C; de Toni F; Scotland S; David M; Danet-Desnoyers G; Vergez F; Barreira Y; Collette Y; Récher C; Sarry JE
Blood Cancer J; 2015 Mar; 5(3):e297. PubMed ID: 25794133
[TBL] [Abstract][Full Text] [Related]
3. Patient-Derived Xenograft Models for Leukemias.
Brown FC; Carmichael CL
Methods Mol Biol; 2024; 2806():31-40. PubMed ID: 38676794
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
[TBL] [Abstract][Full Text] [Related]
5. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
[TBL] [Abstract][Full Text] [Related]
6. How to establish acute myeloid leukemia xenograft models using immunodeficient mice.
Shan WL; Ma XL
Asian Pac J Cancer Prev; 2013; 14(12):7057-63. PubMed ID: 24460250
[TBL] [Abstract][Full Text] [Related]
7. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
[TBL] [Abstract][Full Text] [Related]
8. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
9. Transduction of Primary AML Cells with Lentiviral Vector for
Schimmer AD; Singh RP; Seneviratne AK; Thomas GE; MacLean N; Hurren R
STAR Protoc; 2020 Dec; 1(3):100163. PubMed ID: 33377057
[TBL] [Abstract][Full Text] [Related]
10. Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models.
Olesinski EA; Bhatt S
STAR Protoc; 2021 Jun; 2(2):100461. PubMed ID: 34027474
[TBL] [Abstract][Full Text] [Related]
11. Establishment and Use of Patient-Derived Xenograft Models for Drug Testing in Head and Neck Squamous Cell Carcinoma.
Karamboulas C; Meens J; Ailles L
STAR Protoc; 2020 Jun; 1(1):100024. PubMed ID: 33111077
[TBL] [Abstract][Full Text] [Related]
12. Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.
Sivagnanalingam U; Balys M; Eberhardt A; Wang N; Myers JR; Ashton JM; Becker MW; Calvi LM; Mendler JH
PLoS One; 2015; 10(7):e0132375. PubMed ID: 26177509
[TBL] [Abstract][Full Text] [Related]
13. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.
Wunderlich M; Mizukawa B; Chou FS; Sexton C; Shrestha M; Saunthararajah Y; Mulloy JC
Blood; 2013 Mar; 121(12):e90-7. PubMed ID: 23349390
[TBL] [Abstract][Full Text] [Related]
14. LGALS1 acts as a pro-survival molecule in AML.
Ruvolo PP; Ma H; Ruvolo VR; Zhang X; Post SM; Andreeff M
Biochim Biophys Acta Mol Cell Res; 2020 Oct; 1867(10):118785. PubMed ID: 32590026
[TBL] [Abstract][Full Text] [Related]
15. An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
Vick B; Rothenberg M; Sandhöfer N; Carlet M; Finkenzeller C; Krupka C; Grunert M; Trumpp A; Corbacioglu S; Ebinger M; André MC; Hiddemann W; Schneider S; Subklewe M; Metzeler KH; Spiekermann K; Jeremias I
PLoS One; 2015; 10(3):e0120925. PubMed ID: 25793878
[TBL] [Abstract][Full Text] [Related]
16. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia.
Her Z; Yong KSM; Paramasivam K; Tan WWS; Chan XY; Tan SY; Liu M; Fan Y; Linn YC; Hui KM; Surana U; Chen Q
J Hematol Oncol; 2017 Oct; 10(1):162. PubMed ID: 28985760
[TBL] [Abstract][Full Text] [Related]
17. Protocol to establish a stable
Lu J; Zhao H; Yang L; Jiang X
STAR Protoc; 2022 Sep; 3(3):101559. PubMed ID: 35874469
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
[TBL] [Abstract][Full Text] [Related]
19. ImmunoPET, [
Srideshikan SM; Brooks J; Zuro D; Kumar B; Sanchez J; Echavarria Parra L; Orellana M; Vishwasrao P; Nair I; Chea J; Poku K; Bowles N; Miller A; Ebner T; Molnar J; Rosenthal J; Vallera DA; Wong JYC; Stein AS; Colcher D; Shively JE; Yazaki PJ; Hui SK
Clin Cancer Res; 2019 Dec; 25(24):7463-7474. PubMed ID: 31548348
[TBL] [Abstract][Full Text] [Related]
20. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
Feuring-Buske M; Frankel A; Gerhard B; Hogge D
Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
